Mint Tower Capital Management’s Psyence Biomedical Warrant PBMWW Stock Holding History

Mint Tower Capital Management’s Portfolio PBMWW Stock Details PBMWW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1K	Hold	50,000	–	–	﹤0.01%	341
2026 Q1	$1K	Hold	50,000	–	–	﹤0.01%	335
2025 Q4	$1K	Hold	50,000	–	–	﹤0.01%	263
2025 Q3	$1K	Hold	50,000	–	–	﹤0.01%	200
2025 Q2	$1K	Hold	50,000	–	–	﹤0.01%	158
2025 Q1	$1K	Hold	50,000	–	–	﹤0.01%	145
2024 Q4	$1K	Hold	50,000	–	–	﹤0.01%	141
2024 Q3	$1K	Hold	50,000	–	–	﹤0.01%	145
2024 Q2	$1K	Hold	50,000	–	–	﹤0.01%	136
2024 Q1	$4K	Buy	+50,000	New	+$3.12K	﹤0.01%	165

Other funds holding PBMWW

HCI

Harraden Circle Investments New York $784M AUM 20.59% 1-Year Est. Return

PAMP

Polar Asset Management Partners Toronto, Ontario, Canada $6.07B AUM 34.81% 1-Year Est. Return

MMCAP International Grand Cayman, Cayman Islands $1.18B AUM 50.44% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return

Calamos Advisors Naperville, Illinois $30.1B AUM 30.03% 1-Year Est. Return

SCM

Saba Capital Management New York $3.9B AUM 12.9% 1-Year Est. Return

Clear Street New York $39.5B AUM 124.03% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

LMR Partners London, United Kingdom $26.8B AUM 68.38% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Mint Tower Capital Management's PBMWW Position: Q2 2026 in Review

Mint Tower Capital Management held its Psyence Biomedical Warrant (PBMWW) position steady in Q2 2026 at 50,000 shares worth $1K. The position accounts for ﹤0.01% of the portfolio, ranked #341.

Mint Tower Capital Management first reported a position in PBMWW in Q1 2024 and has held it in 10 quarters since. The position peaked at $4K in Q1 2024. 18 funds tracked by Wall St. Rank hold PBMWW as of Q2 2026.

Mint Tower Capital Management held 50,000 shares of Psyence Biomedical Warrant worth $1K as of Q2 2026.
Mint Tower Capital Management left its Psyence Biomedical Warrant share count unchanged in Q2 2026.
Psyence Biomedical Warrant made up ﹤0.01% of Mint Tower Capital Management's portfolio in Q2 2026, its #341 holding.
Mint Tower Capital Management first reported a position in Psyence Biomedical Warrant in Q1 2024 and has held it in 10 quarters since.
Mint Tower Capital Management's Psyence Biomedical Warrant position peaked at $4K in Q1 2024.
18 funds tracked by Wall St. Rank held Psyence Biomedical Warrant as of Q2 2026.

Based on Mint Tower Capital Management's 13F filing for Q2 2026, filed 18 Aug 2026.